1260403-65-3

Upstream product

• 1260403-62-0 α-hydroxy-3,5-difluoroacetophenone 
• 1260403-63-1 α-acetoxy-3,5-difluoroacetophenone 
• 1260403-64-2 4-(3,5-difluorophenyl)-5H-[1,2,3]-oxathiazole 2,2-dioxide 
• 461-96-1 3,5-difluorobromobenzene 

Downstream Products

• 1260403-66-4 C₁₅H₂₀F₂N₂O₅S 
• 957121-89-0 ethyl [(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]acetate 
• 957118-49-9 [3H]-MK 3207 
• 1260403-67-5 C₁₄H₁₆F₂N₂O 
• 957187-34-7 C₁₆H₁₈F₂N₂O₃ 

Relevant academic research and scientific papers

Practical asymmetric synthesis of a chiral piperazinone derivative

A practical asymmetric route to a chiral piperazinone derivative, a fragment of MK-3207, is reported. The amine-bearing benzylic stereocenter is introduced via an asymmetric Pd-catalyzed hydrogenation of a cyclic sulfimidate in the presence of a chiral phosphine ligand. An efficient synthesis of the hydrogenation substrate is described, together with process development of the hydrogenation step and elaboration of the resulting cyclic sulfamate product to the desired piperazinone.

PROCESS FOR MAKING CGRP RECEPTOR ANTAGONIST

The invention encompasses a novel process for making 2-[(8R)-8-(3,5-Difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]-N-[(2R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl]acetamide, which is a CGRP receptor antagonist useful for the treatment of migraine, using an asymmetric phase-transfer catalysis route. The invention also encompasses an efficient and practical synthesis of the (R)-acid intermediate, and generates the benzylic stereocenter in an enantioselective manner.